Latent or lytic infection? Doesn't matter, Danish biotech says for transplant-related cytomegalovirus drug
Most people in the world have cytomegalovirus, or CMV for short, but it has no effect. However, for some immunocompromised individuals and newborns, the usually harmless virus can cause serious disease involving fever, nausea and vomiting. In transplant patients who have to take immunosuppressive meds, an active CMV infection can also raise the chance of organ rejection.
Those transplant patients at risk for CMV infection are the group that Denmark-based biotech Synklino is hoping to treat with its drug candidate, dubbed SYN002. The biotech has raised €29.8 million ($31.9 million) to move that candidate towards clinical trials, it announced today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.